Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
LifeNet Health currently maintains 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 6 distinct examiners, indicating a range of individual reviews. Furthermore, these matters are spread across 5 distinct art units, which shows that the company's patent applications are being reviewed by multiple different groups within the patent office. The presence of 5 distinct art units requires a prosecution strategy that can address the varying standards of 5 different administrative units within the Biotechnology & Pharmaceuticals field.
The busiest examiner for the portfolio is BERKE-SCHLESSEL, DAVID W, who is currently managing 1 pending office action. With 6 pending actions and 6 distinct examiners, the workload is distributed, with no single examiner holding multiple cases. This distribution requires the company to manage multiple simultaneous prosecution timelines and address the specific examination styles of 6 different individuals. Because the active office actions are not concentrated under a single examiner, the company must maintain its technical arguments across the assigned art units involved in the review process.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (14%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 4 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERKE-SCHLESSEL, DAVID W | 1 | 66.7% | +31.8% |
| HERBERT, MADISON TAYLOR | 1 | 59.1% | +53.7% |
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
| ALEMAN, SARAH WEBB | 1 | 62.1% | +23.7% |
| BATES, KEENAN ALEXANDER | 1 | 45.5% | +79.5% |
| STAVROU, CONSTANTINA E | 1 | 43.7% | +36.9% |
| VAN BUREN, LAUREN K | 1 | 39.8% | +58.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17731616 | PRESERVATION METHODS USING TREHALOSE WITH OTHER CRYOPROTECTANTS BEING ABSENT FROM THE CRYOPRESERVATION PROTOCOL | JOHNSON, ALLISON MARIE | 62d |
| 17987257 | CASSETTE FOR PRESERVATION OF NATURAL AND BIOENGINEERED TISSUES | HERBERT, MADISON TAYLOR | — |
| 17695170 | AORTOILIAC IMPLANT AND PROCESSING AND USES THEREOF | ALEMAN, SARAH WEBB | — |
| 17506140 | MINIMIZING IMMUNOGENICITY OF DECELLULARIZED TISSUES | BATES, KEENAN ALEXANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17088860 | ICE-FREE VITRIFICATION AND NANO WARMING OF LARGE TISSUE SAMPLES | VAN BUREN, LAUREN K | 72d overdue |
| 17731616 | PRESERVATION METHODS USING TREHALOSE WITH OTHER CRYOPROTECTANTS BEING ABSENT FROM THE CRYOPRESERVATION PROTOCOL | JOHNSON, ALLISON MARIE | 62d |
| 18757079 | CROSSLINKED SOFT TISSUE GRAFT AND METHODS OF USE THEREOF | BERKE-SCHLESSEL, DAVID W | — |
| 17987257 | CASSETTE FOR PRESERVATION OF NATURAL AND BIOENGINEERED TISSUES | HERBERT, MADISON TAYLOR | — |
| 17695170 | AORTOILIAC IMPLANT AND PROCESSING AND USES THEREOF | ALEMAN, SARAH WEBB | — |
| 17506140 | MINIMIZING IMMUNOGENICITY OF DECELLULARIZED TISSUES | BATES, KEENAN ALEXANDER | — |
| 17603661 | BIRTH TISSUE-DERIVED PRODUCTS AND PREPARATION AND USES THEREOF | STAVROU, CONSTANTINA E | — |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| 1651 | 1 |
| 1758 | 1 |
| 3774 | 1 |
| 1631 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18757079 | CROSSLINKED SOFT TISSUE GRAFT AND METHODS OF USE THEREOF | BERKE-SCHLESSEL, DAVID W | 1651 | §112DP | Non-Final OA | — | Pending | Jun 27, 2024 |
| 17987257 | CASSETTE FOR PRESERVATION OF NATURAL AND BIOENGINEERED TISSUES | HERBERT, MADISON TAYLOR | 1758 | §102§103 | Final Rejection | — | Pending | Nov 15, 2022 |
| 17731616 | PRESERVATION METHODS USING TREHALOSE WITH OTHER CRYOPROTECTANTS BEING ABSENT FROM THE CRYOPRESERVATION PROTOCOL | JOHNSON, ALLISON MARIE | 1638 | §102§103§112 | Non-Final OA | 62d | Pending | Apr 28, 2022 |
| 17695170 | AORTOILIAC IMPLANT AND PROCESSING AND USES THEREOF | ALEMAN, SARAH WEBB | 3774 | §103§112 | Final Rejection | — | Pending | Mar 15, 2022 |
| 17506140 | MINIMIZING IMMUNOGENICITY OF DECELLULARIZED TISSUES | BATES, KEENAN ALEXANDER | 1631 | §103§112 | Non-Final OA | — | Pending | Oct 20, 2021 |
| 17603661 | BIRTH TISSUE-DERIVED PRODUCTS AND PREPARATION AND USES THEREOF | STAVROU, CONSTANTINA E | 1632 | §102 | Final Rejection | — | Pending | Oct 14, 2021 |
| 17088860 | ICE-FREE VITRIFICATION AND NANO WARMING OF LARGE TISSUE SAMPLES | VAN BUREN, LAUREN K | 1638 | §112DP | Final Rejection | 72d overdue | Pending | Nov 04, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial